Head-To-Head Survey: Revolution Medicines (NASDAQ:RVMD) & Osiris Therapeutics (OTCMKTS:OSIR)

Revolution Medicines (NASDAQ:RVMD) and Osiris Therapeutics (OTCMKTS:OSIR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Valuation & Earnings

This table compares Revolution Medicines and Osiris Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58 million	649.13	-$436.37 million	($3.75)	-12.15
Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A

Osiris Therapeutics has lower revenue, but higher earnings than Revolution Medicines.

Institutional & Insider Ownership

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 0.3% of Osiris Therapeutics shares are owned by institutional investors. 8.0% of Revolution Medicines shares are owned by insiders. Comparatively, 43.4% of Osiris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Revolution Medicines and Osiris Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-36.41%	-32.13%
Osiris Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Revolution Medicines and Osiris Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	0	0	11	1	3.08
Osiris Therapeutics	0	0	0	0	N/A

Revolution Medicines currently has a consensus price target of $50.67, suggesting a potential upside of 11.21%. Given Revolution Medicines’ higher probable upside, analysts plainly believe Revolution Medicines is more favorable than Osiris Therapeutics.

Summary

Revolution Medicines beats Osiris Therapeutics on 5 of the 8 factors compared between the two stocks.

About Revolution Medicines

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

About Osiris Therapeutics

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.